Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 13NIH 5INDUSTRY 4

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 9Genitourinary 8Gastrointestinal 8Sarcoma 5Gynecologic 4CNS 3Breast 3Other solid neoplasm 2Lymphoid 2Head & Neck 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Sarcoma, Alveolar Soft Part 3Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Rhabdoid Tumor 1Melanoma 1Lymphoma, Follicular 1Chordoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 43Temozolomide 34Magnetic Resonance Spectroscopy 33Doxorubicin 33Specimen Handling 31Cyclophosphamide 31Vincristine 24Etoposide 21Radiation 20Biopsy 20Ifosfamide 19Filgrastim 18Sirolimus 15Bevacizumab 15temsirolimus 14Sorafenib 13X-Rays 12Surgical Procedures, Operative 12Nivolumab 12Imatinib Mesylate 12Carboplatin 12Radiotherapy, Conformal 11Methotrexate 11Ipilimumab 11Vorinostat 10Peripheral Blood Stem Cell Transplantation 10Irinotecan 10Immunoglobulin G 10Disulfides 10Chemotherapy, Adjuvant 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NIH × atezolizumab × Sarcoma × Clear all
NCT06066138 2026-06-04

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
30 enrolled
DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT03141684 2026-06-03

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
63 enrolled 1 FDA
Sarcoma

Sarcoma, Alveolar Soft Part

NCT04458922 2026-06-02

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
27 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05333458 2026-05-13

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
27 enrolled
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡